Pub Date : 2026-02-02DOI: 10.1016/s1470-2045(26)00013-6
Bishal Gyawali, Samuel X Stevens, Laure-Anne Teuwen
{"title":"Factors that can make overall survival unreliable as a clinical trial outcome – Authors' reply","authors":"Bishal Gyawali, Samuel X Stevens, Laure-Anne Teuwen","doi":"10.1016/s1470-2045(26)00013-6","DOIUrl":"https://doi.org/10.1016/s1470-2045(26)00013-6","url":null,"abstract":"","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"39 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146109890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-02DOI: 10.1016/s1470-2045(25)00706-5
David J Stewart, Vivek Subbiah, Mathew Vogel, Tim Ramsay, Razelle Kurzrock
{"title":"Factors that can make overall survival unreliable as a clinical trial outcome","authors":"David J Stewart, Vivek Subbiah, Mathew Vogel, Tim Ramsay, Razelle Kurzrock","doi":"10.1016/s1470-2045(25)00706-5","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00706-5","url":null,"abstract":"","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"87 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146109910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-02DOI: 10.1016/s1470-2045(25)00669-2
Dylan E Graetz, Bryan A Sisk, Marta Salek, Lindsay J Blazin, Claire E Wakefield, Elise C Tarbi, Sally Thorne, Thomas W LeBlanc, Pamela S Hinds, Lara Traeger, Erica C Kaye
This Review underscores qualitative research as an indispensable facet of scientific inquiry to improve provision of safe, effective, and affordable care for patients with cancer worldwide. Representing a global working group of applied qualitative researchers, our multidisciplinary authorship team defines qualitative research, characterises its purpose and value, and describes specific ways in which qualitative inquiry is central to advancing cures, treatment, and quality of life in oncology. In this Review, we put forward an imperative for the use of qualitative methods to assess context, understand population needs, design interventions, optimise implementation, and investigate mechanisms of action underpinning changes in health outcomes. We highlight the ways in which qualitative methods capture cultural context, making them crucial for scientific inquiry, and discuss the importance of using qualitative research to define research priorities, uncover and address understudied topics, and elevate marginalised voices globally. Ultimately, this Review serves as a call to action for improved integration of qualitative scholarship across each stage of cancer research and establishes a roadmap for collaboration among clinicians, scientists, publishers, and funders to recognise qualitative research as essential for scientific advancement in the field of oncology.
{"title":"The power of words: evaluating the role of qualitative methods in cancer research","authors":"Dylan E Graetz, Bryan A Sisk, Marta Salek, Lindsay J Blazin, Claire E Wakefield, Elise C Tarbi, Sally Thorne, Thomas W LeBlanc, Pamela S Hinds, Lara Traeger, Erica C Kaye","doi":"10.1016/s1470-2045(25)00669-2","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00669-2","url":null,"abstract":"This Review underscores qualitative research as an indispensable facet of scientific inquiry to improve provision of safe, effective, and affordable care for patients with cancer worldwide. Representing a global working group of applied qualitative researchers, our multidisciplinary authorship team defines qualitative research, characterises its purpose and value, and describes specific ways in which qualitative inquiry is central to advancing cures, treatment, and quality of life in oncology. In this Review, we put forward an imperative for the use of qualitative methods to assess context, understand population needs, design interventions, optimise implementation, and investigate mechanisms of action underpinning changes in health outcomes. We highlight the ways in which qualitative methods capture cultural context, making them crucial for scientific inquiry, and discuss the importance of using qualitative research to define research priorities, uncover and address understudied topics, and elevate marginalised voices globally. Ultimately, this Review serves as a call to action for improved integration of qualitative scholarship across each stage of cancer research and establishes a roadmap for collaboration among clinicians, scientists, publishers, and funders to recognise qualitative research as essential for scientific advancement in the field of oncology.","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"82 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146101570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-02DOI: 10.1016/s1470-2045(25)00760-0
Simon K B Spohn, Anca-Ligia Grosu
{"title":"Oligometastatic prostate cancer: time to integrate metastasis-directed therapy","authors":"Simon K B Spohn, Anca-Ligia Grosu","doi":"10.1016/s1470-2045(25)00760-0","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00760-0","url":null,"abstract":"","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"39 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146109903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-02DOI: 10.1016/s1470-2045(25)00756-9
Dirk De Ruysscher, Pim J J Damen, Lizza E L Hendriks, Stephanie P L Saw
{"title":"Radiotherapy has a role to play in patients with EGFR-mutated non-small-cell lung cancer in first-line treatment","authors":"Dirk De Ruysscher, Pim J J Damen, Lizza E L Hendriks, Stephanie P L Saw","doi":"10.1016/s1470-2045(25)00756-9","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00756-9","url":null,"abstract":"","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"294 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146109913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-02DOI: 10.1016/s1470-2045(25)00757-0
Cattley RC, De Roos AJ, Mandrioli D, et al. Carcinogenicity of atrazine, alachlor, and vinclozolin. Lancet Oncol 2026; 27: 11–12—In this News, the meta-odds ratio in the second sentence of the fifth paragraph should have been 1·99; 95% CI 1·13–3·53. This correction has been made to the online version as of Feb 2, 2026.
{"title":"Correction to Lancet Oncol 2026; 27: 11–12","authors":"","doi":"10.1016/s1470-2045(25)00757-0","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00757-0","url":null,"abstract":"<em>Cattley RC, De Roos AJ, Mandrioli D, et al. Carcinogenicity of atrazine, alachlor, and vinclozolin.</em> Lancet Oncol <em>2026; <strong>27:</strong> 11–12</em>—In this News, the meta-odds ratio in the second sentence of the fifth paragraph should have been 1·99; 95% CI 1·13–3·53. This correction has been made to the online version as of Feb 2, 2026.","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"89 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146101567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-02DOI: 10.1016/s1470-2045(25)00648-5
Camille Maringe, Daniel O’Leary, Sara Benitez-Majano, Clemence Leyrat, Aimilia Exarchakou, Bernard Rachet, Manuela Quaresma
<h3>Background</h3>Minimally invasive surgical resection offers advantages over open surgical resection in elective management of colon cancer. However, patients who are older, have comorbidities, or live in socioeconomically deprived areas are less likely to receive minimally invasive surgical resection. We aimed to estimate the potential effect on outcomes of correcting inequalities in minimally invasive surgical resection for colon cancer.<h3>Methods</h3>In this population-based study, we studied adult patients (aged 15–99 years) diagnosed with stage I–III carcinoma of the colon between Jan 1 and Dec 31, 2022, and followed up to Dec 31, 2023, who underwent elective resection as recorded in linked cancer registration data in England. We excluded patients diagnosed through an emergency route, diagnosed with metastatic disease (stage IV), with missing stage, not resected, and who underwent colon cancer surgery in a private hospital or in a UK National Health Service (NHS) Trust that recorded ten or fewer colon cancer resections in 2022. Only Trusts doing both minimally invasive surgical and open surgical resections were included to ensure correct modelling of the effect of correcting inequalities in minimally invasive surgical resections within each Trust. We designed scenarios to correct inequalities in minimally invasive surgical resection in each UK NHS Trust, targeting four suboptimal uptake groups (patients who were aged 65 years and older, patients with frailty, patients with comorbidities, and patients with high levels of socioeconomic deprivation). We used a potential outcomes framework and contrasted observed and potential outcomes to estimate the effect of reducing inequalities in use of minimally invasive surgical resection on four primary outcomes: the lengths of index stay and total hospital stay, the probability of readmission within 30 days of resection, and 1-year mortality after resection.<h3>Findings</h3>All analyses included data for 10 603 elective colon resections done in 123 NHS Trusts. The median follow-up time was 1·47 years (IQR 1·22–1·74). The mean age at diagnosis was 70·3 years (SD 11·4). 5487 (51·7%) patients were male and 5116 (48·3%) were female. Minimally invasive surgical resection was attempted in 8909 (84·0%) and completed in 7951 (75·0%), among whom there were substantial inequalities in the proportion of minimally invasive surgical resections among the four suboptimal uptake groups defined by age at diagnosis of 65 years and older (5495 [73·8%] <em>vs</em> 2456 [77·8%] in those younger than 65 years), most deprived quintiles (quintiles 3–5: 4114 [73·9%] <em>vs</em> 3837 [76·2%] in the least deprived quintiles), comorbidity (2348 [70·8%] <em>vs</em> 5603 [76·9%] in those without comorbidities), and a moderate or high frailty score (695 [64·1%] <em>vs</em> 7256 [76·2%] in those with a low frailty score). Patients with minimally invasive surgical resection had 3-day to 4-day shorter lengths of hospital stay than
{"title":"Estimated effect of correcting inequalities in minimally invasive surgical resection in patients with colon cancer in England: a population-based study","authors":"Camille Maringe, Daniel O’Leary, Sara Benitez-Majano, Clemence Leyrat, Aimilia Exarchakou, Bernard Rachet, Manuela Quaresma","doi":"10.1016/s1470-2045(25)00648-5","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00648-5","url":null,"abstract":"<h3>Background</h3>Minimally invasive surgical resection offers advantages over open surgical resection in elective management of colon cancer. However, patients who are older, have comorbidities, or live in socioeconomically deprived areas are less likely to receive minimally invasive surgical resection. We aimed to estimate the potential effect on outcomes of correcting inequalities in minimally invasive surgical resection for colon cancer.<h3>Methods</h3>In this population-based study, we studied adult patients (aged 15–99 years) diagnosed with stage I–III carcinoma of the colon between Jan 1 and Dec 31, 2022, and followed up to Dec 31, 2023, who underwent elective resection as recorded in linked cancer registration data in England. We excluded patients diagnosed through an emergency route, diagnosed with metastatic disease (stage IV), with missing stage, not resected, and who underwent colon cancer surgery in a private hospital or in a UK National Health Service (NHS) Trust that recorded ten or fewer colon cancer resections in 2022. Only Trusts doing both minimally invasive surgical and open surgical resections were included to ensure correct modelling of the effect of correcting inequalities in minimally invasive surgical resections within each Trust. We designed scenarios to correct inequalities in minimally invasive surgical resection in each UK NHS Trust, targeting four suboptimal uptake groups (patients who were aged 65 years and older, patients with frailty, patients with comorbidities, and patients with high levels of socioeconomic deprivation). We used a potential outcomes framework and contrasted observed and potential outcomes to estimate the effect of reducing inequalities in use of minimally invasive surgical resection on four primary outcomes: the lengths of index stay and total hospital stay, the probability of readmission within 30 days of resection, and 1-year mortality after resection.<h3>Findings</h3>All analyses included data for 10 603 elective colon resections done in 123 NHS Trusts. The median follow-up time was 1·47 years (IQR 1·22–1·74). The mean age at diagnosis was 70·3 years (SD 11·4). 5487 (51·7%) patients were male and 5116 (48·3%) were female. Minimally invasive surgical resection was attempted in 8909 (84·0%) and completed in 7951 (75·0%), among whom there were substantial inequalities in the proportion of minimally invasive surgical resections among the four suboptimal uptake groups defined by age at diagnosis of 65 years and older (5495 [73·8%] <em>vs</em> 2456 [77·8%] in those younger than 65 years), most deprived quintiles (quintiles 3–5: 4114 [73·9%] <em>vs</em> 3837 [76·2%] in the least deprived quintiles), comorbidity (2348 [70·8%] <em>vs</em> 5603 [76·9%] in those without comorbidities), and a moderate or high frailty score (695 [64·1%] <em>vs</em> 7256 [76·2%] in those with a low frailty score). Patients with minimally invasive surgical resection had 3-day to 4-day shorter lengths of hospital stay than ","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"67 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146109893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-02DOI: 10.1016/s1470-2045(25)00602-3
Malignant spinal cord compression (MSCC) is a serious complication of spinal metastases and primary spinal tumours that can severely affect quality of…
恶性脊髓压迫（MSCC）是脊髓转移瘤和原发性脊髓肿瘤的严重并发症，可严重影响脊髓质量。
{"title":"International Multidisciplinary Consensus Group for Malignant Spinal Cord Compression: recommendations for definitions, reporting items, and study endpoints for clinical trials and audits","authors":"","doi":"10.1016/s1470-2045(25)00602-3","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00602-3","url":null,"abstract":"Malignant spinal cord compression (MSCC) is a serious complication of spinal metastases and primary spinal tumours that can severely affect quality of…","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"8 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146101573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：